Logo image
HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix: A population-based study from Northern Ireland
Journal article   Peer reviewed

HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix: A population-based study from Northern Ireland

Lesley A Anderson, Michael A O'Rorke, Robbie Wilson, Jackie Jamison, Anna T Gavin and Northern Ireland HPV Working Group
Journal of medical virology, Vol.88(7), pp.1262-1270
07/2016
DOI: 10.1002/jmv.24447
PMID: 26680281
url
https://pure.qub.ac.uk/en/publications/e7c97307-47f0-4ad9-bd20-f369b2b65967View
Open Access

Abstract

Assessment of Human papillomavirus (HPV) prevalence and genotype distribution is important for monitoring the impact of prophylactic HPV vaccination. This study aimed to demonstrate the HPV genotypes predominating in pre-malignant and cervical cancers in Northern Ireland (NI) before the vaccination campaign has effect. Formalin fixed paraffin embedded tissue blocks from 2,303 women aged 16-93 years throughout NI were collated between April 2011 and February 2013. HPV DNA was amplified by PCR and HPV genotyping undertaken using the Roche(®) linear array detection kit. In total, 1,241 out of 1,830 eligible samples (68.0%) tested positive for HPV, with the majority of these [1,181/1,830 (64.5%)] having high-risk (HR) HPV infection; 37.4% were positive for HPV-16 (n = 684) and 5.1% for HPV-18 (n = 93). HPV type-specific prevalence was 48.1%, 65.9%, 81.3%, 92.2%, and 64.3% among cervical intraepithelial neoplasias (CIN) Grades I-III, squamous cell carcinomas (SCC) and adenocarcinoma (AC) cases, respectively. Most SCC cases (81.3%) had only one HPV genotype detected and almost a third (32.0%) of all cervical pathologies were HPV negative including 51.9% of CIN I (n = 283), 34.1% CIN II (n = 145), 18.7% of CIN III (n = 146), 7.8% of SCC (n = 5), and 35.7% of AC (n = 5) cases. This study provides important baseline data for monitoring the effect of HPV vaccination in NI and for comparison with other UK regions. The coverage of other HR-HPV genotypes apart from 16 and 18, including HPV-45, 31, 39, and 52, and the potential for cross protection, should be considered when considering future polyvalent vaccines.
Polymerase Chain Reaction Prevalence Human papillomavirus 16 - classification Carcinoma, Squamous Cell - virology Humans Uterine Cervical Neoplasms - epidemiology DNA, Viral - analysis Human papillomavirus 16 - isolation & purification Adult Cervix Uteri - pathology Female Papillomavirus Infections - virology Cervical Intraepithelial Neoplasia - epidemiology Human papillomavirus 18 - genetics Cervix Uteri - virology Carcinoma, Squamous Cell - epidemiology Papillomavirus Infections - epidemiology Risk Factors Genotype Ireland - epidemiology Adenocarcinoma - virology Cervical Intraepithelial Neoplasia - virology Human papillomavirus 18 - isolation & purification Uterine Cervical Neoplasms - virology Northern Ireland - epidemiology Aged Human papillomavirus 18 - classification Adenocarcinoma - epidemiology Human papillomavirus 16 - genetics

Details

Metrics

Logo image